company background image
SLDB

Solid Biosciences NasdaqGS:SLDB Stock Report

Last Price

US$0.58

Market Cap

US$65.0m

7D

-3.2%

1Y

-84.2%

Updated

04 Jul, 2022

Data

Company Financials +
SLDB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SLDB Stock Overview

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States.

Solid Biosciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Solid Biosciences
Historical stock prices
Current Share PriceUS$0.58
52 Week HighUS$3.65
52 Week LowUS$0.42
Beta1.54
1 Month Change0.98%
3 Month Change-52.40%
1 Year Change-84.18%
3 Year Change-88.71%
5 Year Changen/a
Change since IPO-97.45%

Recent News & Updates

Apr 30
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

It's shaping up to be a tough period for Solid Biosciences Inc. ( NASDAQ:SLDB ), which a week ago released some...

Apr 28
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

The latest analyst coverage could presage a bad day for Solid Biosciences Inc. ( NASDAQ:SLDB ), with the analysts...

Shareholder Returns

SLDBUS BiotechsUS Market
7D-3.2%0.1%-2.2%
1Y-84.2%-25.1%-19.1%

Return vs Industry: SLDB underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: SLDB underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is SLDB's price volatile compared to industry and market?
SLDB volatility
SLDB Average Weekly Movement13.7%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.3%

Stable Share Price: SLDB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: SLDB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013104Ilan Ganothttps://www.solidbio.com

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company’s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients’ muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids.

Solid Biosciences Fundamentals Summary

How do Solid Biosciences's earnings and revenue compare to its market cap?
SLDB fundamental statistics
Market CapUS$64.98m
Earnings (TTM)-US$80.62m
Revenue (TTM)US$12.21m

5.3x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLDB income statement (TTM)
RevenueUS$12.21m
Cost of RevenueUS$5.74m
Gross ProfitUS$6.47m
Other ExpensesUS$87.09m
Earnings-US$80.62m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.71
Gross Margin53.00%
Net Profit Margin-660.25%
Debt/Equity Ratio0%

How did SLDB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SLDB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLDB?

Other financial metrics that can be useful for relative valuation.

SLDB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SLDB's PS Ratio compare to its peers?

SLDB PS Ratio vs Peers
The above table shows the PS ratio for SLDB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average63.1x
BYSI BeyondSpring
45x52.2%US$60.7m
TCON TRACON Pharmaceuticals
117.8x76.7%US$40.7m
AIMD Ainos
61.6xn/aUS$41.8m
HGEN Humanigen
27.9x31.2%US$115.8m
SLDB Solid Biosciences
5.3x55.0%US$65.0m

Price-To-Sales vs Peers: SLDB is good value based on its Price-To-Sales Ratio (5.3x) compared to the peer average (63.1x).


Price to Earnings Ratio vs Industry

How does SLDB's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: SLDB is good value based on its Price-To-Sales Ratio (5.3x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is SLDB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLDB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.3x
Fair PS Ratio11.6x

Price-To-Sales vs Fair Ratio: SLDB is good value based on its Price-To-Sales Ratio (5.3x) compared to the estimated Fair Price-To-Sales Ratio (11.6x).


Share Price vs Fair Value

What is the Fair Price of SLDB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SLDB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SLDB's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SLDB's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Solid Biosciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-9.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLDB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLDB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLDB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLDB's revenue (55% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: SLDB's revenue (55% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SLDB is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Solid Biosciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-9.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SLDB is currently unprofitable.

Growing Profit Margin: SLDB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SLDB is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.

Accelerating Growth: Unable to compare SLDB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLDB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).


Return on Equity

High ROE: SLDB has a negative Return on Equity (-43.46%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Solid Biosciences's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SLDB's short term assets ($198.6M) exceed its short term liabilities ($21.7M).

Long Term Liabilities: SLDB's short term assets ($198.6M) exceed its long term liabilities ($301.0K).


Debt to Equity History and Analysis

Debt Level: SLDB is debt free.

Reducing Debt: SLDB has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLDB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SLDB has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 8.3% each year.


Discover healthy companies

Dividend

What is Solid Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SLDB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLDB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLDB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLDB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLDB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Ilan Ganot (48 yo)

9.5yrs

Tenure

US$3,293,809

Compensation

Mr. Ilan Ganot is Co- Founder of Solid Biosciences Inc. and has been its Chief Executive Officer and Director since 2013. He serves as the President of Solid Biosciences Inc. since June 26, 2018. He is al...


CEO Compensation Analysis

Compensation vs Market: Ilan's total compensation ($USD3.29M) is above average for companies of similar size in the US market ($USD799.15K).

Compensation vs Earnings: Ilan's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SLDB's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: SLDB's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Top Shareholders

Company Information

Solid Biosciences Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Solid Biosciences Inc.
  • Ticker: SLDB
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$64.980m
  • Shares outstanding: 112.81m
  • Website: https://www.solidbio.com

Number of Employees


Location

  • Solid Biosciences Inc.
  • 141 Portland Street
  • Fifth Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/04 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.